Phase-1 trial: Adenovirus COVID-19 vaccine shows a positive
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans, according to new research published in The Lancet on 23 May.

Key findings:

• The open-label trial in 108 adults healthy adults between the ages of 18 and 60 years, the vaccine produced neutralizing antibodies, and a response mediated by the immune system’s T-cells against SARS-CoV-2.

• Based on the results, the researchers said the vaccine was well tolerated by the volunteers at all doses with no serious adverse events reported within 28 days of vaccination.

• “The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 [Ad5-nCoV] vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation,” says study author Wei Chen, a professor from the Beijing Institute of Biotechnology in China.

• The vaccine demonstrated promising results after 28 days, with the final results to be evaluated in six months, the study said.

• The Ad5 vectored COVID-19 vaccine used in the trial is the first to be tested in humans, the scientists said.

• Further trials are needed to tell whether the immune response it elicits effectively protects against SARS-CoV-2 infection.

Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext
Dr. M●●●●●h R●●●y K S and 25 others like this21 shares
Like
Comment
Share
Dr. S●●●●●m S●●●●y P●●●●●l
Dr. S●●●●●m S●●●●y P●●●●●l General Medicine
It is encouraging news indeed. However,will we ever be able to trust any Chinese biological solutions after this pandemic,or whether their use is even a good idea is a matter of debate.
May 26, 2020Like2